This three-part webcast traces the rapidly evolving story of heart failure therapy across the entire ejection-fraction spectrum. International experts first unpack how SGLT2 inhibitors have “changed the game” in heart failure by consistently reducing cardiovascular death and hospitalizations while improving patient quality of life, regardless of diabetes status. They then explore the changing landscape in HFpEF, highlighting novel evidence for MRAs and finerenone, the promise of GLP-1–based strategies and emerging anti-inflammatory and aldosterone synthase-inhibiting approaches that may finally shift outcomes in this high-risk population. Completing the picture, a dedicated talk on emerging treatment strategies in HFrEF ties these advances back to day-to-day clinical decision-making, showing how to individualize therapy for complex patients.